All In Biotech

NDA 022483 · Bausch

Zyclara

Imiquimod · Topical

Last checked: Nov 20, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Mar 25, 2010

Approved uses

3

Original approval plus efficacy supplements

Registered trials

185

42 Phase 3, 12 recruiting

FAERS reports

2,334

1,287 serious, 73 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2025.

Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. ( 1.1 ) Imiquimod Cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age or older. ( 1.2 ) 1.1 Actinic Keratosis Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. 1.2 External Genital Warts Imiquimod Cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age and older.

Mechanism: The mechanism of action of Imiquimod Cream in the treatment of AK and EGW is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ZYCLARA · IMIQUIMOD 3.75% · CREAM, TOPICAL · Prescription · TE AB
  • ZYCLARA · IMIQUIMOD 2.5% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Imiquimod" as an intervention, any sponsor and status, largest first.

All 185 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use265
  • erythema185
  • fatigue181
  • product use in unapproved indication177
  • drug ineffective171
  • pain137
  • nausea114
  • influenza like illness103
  • application site erythema102
  • headache95
  • pruritus88
  • pyrexia85

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20052
20069
20071
20087
200911
201015
201155
201264
201369
201464
2015119
2016198
2017220
2018216
2019185
2020211
2021110
2022166
2023163
2024117
2025180
2026148

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zyclara (Imiquimod)

2024 spending

$104K

Beneficiaries

59

81 claims

Per beneficiary

$1,755

$151.05 per unit

View as table
YearSpending
2020$310,475
2021$141,752
2022$97,897
2023$115,077
2024$103,572

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 462 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.